PMID- 21295491
OWN - NLM
STAT- MEDLINE
DCOM- 20110621
LR  - 20220330
IS  - 1096-3618 (Electronic)
IS  - 1044-5323 (Linking)
VI  - 23
IP  - 1
DP  - 2011 Feb
TI  - Harnessing dendritic cells in cancer.
PG  - 42-9
LID - 10.1016/j.smim.2011.01.003 [doi]
AB  - Dendritic cells (DCs) are central to the initiation of tumor-specific immune 
      responses. However, the tumor microenvironment generates immunosuppressive cells 
      and soluble mediators that compromise DC functions and limit the success of 
      DC-based therapies. Progress in understanding DC metabolism in cancer is 
      uncovering novel therapeutic targets that could restore DC capacity to prime T 
      cells and trigger effective anticancer responses. Accumulating evidence also 
      indicates that conventional chemo- and radiotherapy protocols can cause DC 
      activation, enhance antigen cross-presentation, selectively eliminate 
      immunosuppressive cells and revert the immunosuppression state caused by cancer, 
      suggesting that relevant chemoimmunotherapy associations could fully exploit DC 
      capacity to trigger anticancer responses. Here, we discuss recent strategies that 
      harness DC against cancer.
CI  - Copyright (c) 2011 Elsevier Ltd. All rights reserved.
FAU - Apetoh, Lionel
AU  - Apetoh L
AD  - INSERM, U866, Dijon, France.
FAU - Locher, Clara
AU  - Locher C
FAU - Ghiringhelli, Francois
AU  - Ghiringhelli F
FAU - Kroemer, Guido
AU  - Kroemer G
FAU - Zitvogel, Laurence
AU  - Zitvogel L
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20110203
PL  - England
TA  - Semin Immunol
JT  - Seminars in immunology
JID - 9009458
RN  - 0 (Antigens, Neoplasm)
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Cancer Vaccines)
SB  - IM
MH  - Animals
MH  - Antigens, Neoplasm/immunology
MH  - Antineoplastic Agents/therapeutic use
MH  - Cancer Vaccines/immunology/therapeutic use
MH  - Dendritic Cells/*immunology
MH  - Disease Models, Animal
MH  - Humans
MH  - Immunotherapy
MH  - Killer Cells, Natural/immunology
MH  - Lymphocyte Activation/immunology
MH  - Neoplasms/*immunology/*therapy
MH  - T-Lymphocytes/immunology
MH  - Tumor Microenvironment/immunology
EDAT- 2011/02/08 06:00
MHDA- 2011/06/22 06:00
CRDT- 2011/02/08 06:00
PHST- 2010/09/15 00:00 [received]
PHST- 2011/01/05 00:00 [accepted]
PHST- 2011/02/08 06:00 [entrez]
PHST- 2011/02/08 06:00 [pubmed]
PHST- 2011/06/22 06:00 [medline]
AID - S1044-5323(11)00004-2 [pii]
AID - 10.1016/j.smim.2011.01.003 [doi]
PST - ppublish
SO  - Semin Immunol. 2011 Feb;23(1):42-9. doi: 10.1016/j.smim.2011.01.003. Epub 2011 
      Feb 3.